Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human Interleukin-1 Receptor Antagonist, Anakinra, to Prevent Post-infarction Remodeling: the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART)

NCT00789724 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT00789724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00789724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human Interleukin-1 Receptor Antagonist, Anakinra, to Prevent Post-infarction Remodeling: the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART)
Lead sponsor
Virginia Commonwealth University
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2008
Completion date
August 31, 2009
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

st segment elevation acute myocardial infarction